Company intelligence / Profile preview

Inven2

Ownership: Private
Employees: ~34
Development stage: Other

Overview

Inven2 does not conduct clinical trials on its own products but manages clinical trial agreements on behalf of hospitals and supports the commercialization of academic research into products/services. Its impact includes over NOK 11 billion in portfolio value as of December 2023 with more than fifty established companies and numerous licensed technologies/products now on the market.

Therapeutic areas: OncologyRare DiseasesGastroenterologyCardiovascularInfectious Diseases
Modalities: Monoclonal antibody (via licensed antibody technology)Small molecule (across portfolio companies)Medical device (across portfolio companies)Gene therapy and others possible via portfolio but not directly specified for Inven2 itself
Industry: Investors

Partnerships

Tillotts Pharma AG/Zeria Pharmaceutical Co., Ltd. – licensing agreement for proprietary antibody technology targeting IBDNumerous partnerships with Norwegian hospitals/universities

Beyond the preview

Go deeper on Inven2.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inven2.

Explore the full profile